• RNA/DNA
  • Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

    Apr 23, 2023

    Contact us to request a quote or test sample!  

    Following the filings of our GMP-Grade BsaI and GMP-Grade T7 RNA Polymerase, several other mRNA synthesis enzymes from KACTUS have been successfully submitted to the FDA Drug Master Files. Below is the full list of mRNA synthesis enzymes that have been submitted:

    Product DMF #
    BsaI 037503
    T7 RNA Polymerase 037660
    Vaccinia Capping Enzyme 038028
    mRNA Cap 2'-O-Methyltransferase 038029
    Pyrophosphatase, Inorganic 038030
    Murine RNase Inhibitor 038031
    DNase I 038032

    GMP-Grade Enzyme Manufacturing

    KACTUS has established a GMP-Grade quality management system and documented it in accordance with the relevant requirements of cGMP and ISO13485:2016 guidelines. We take a variety of steps to ensure complete control over the manufacturing and release process and to ensure the quality of our GMP-Grade products meet the strict requirements of drug manufacturing.

    → Produced and quality control tested in adherence to GMP standards

    → High standard protease GMP production workshop

    → Manufacturing Execution System (MES) digital production management system

    → Analytical method validation and process validation with reference to regulatory requirements

    → Batch-to-batch stability and consistency

    → Free from antibiotic residues

    → Free from raw materials of animal origin

    → Supporting regulatory documentation reviewed & approved by Quality Assurance

    → Comprehensive records for batch production and control

    → Developed following ISO13485:2016 guidelines

    → Pharmaceutical Class A & C Clean Room

    → Validated and maintained equipment

    → Stability Testing 

    Comprehensive Quality Release Verification: T7 RNA Polymerase
    Activity
    ≥ 50 kU/mL
    Purity (SEC-HPLC)
    ≥ 95%
    Residual Endonuclease
    Negative
    Residual Exonuclease
    Negative
    Residual DNase
    Negative
    Residual RNase
    Negative
    Residual Protease
    Negative
    Endotoxin
    ≤ 10 EU/mL
    Residual Host Cell DNA
    ≤ 100 pg/mg
    Residual Host Protein
    ≤ 20 ng/mg
    Residual Heavy Metal
    ≤ 10ppm
    Bioburden
    ≤ 1 CFU/10mL

     

    Product Data

    Vaccinia Capping Enzyme and mRNA Cap 2'-O-Methyltransferase have strong capping activity

    Figure 1. Detection of Cap1 capping efficiency by LC-MS. Vaccinia Capping Enzyme and mRNA Cap 2'-O-Methyltransferase were used in sequence to add the Cap1 structure to mRNA. Results showed that the capping rate of Cap1 was 99.01%.

    Pyrophosphatase, Inorganic can effectively increase the production of mRNA

    Figure 2. Pyrophosphatase, Inorganic effectively increases mRNA production. Additional inorganic pyrophosphatase was added to a 20μL in vitro transcription system, compared to the same transcription system but without Pyrophosphtase, Inorganic.

    DNase I has high enzymatic activity and can efficiently digest DNA

     Figure 3. DNase I digestion effect on DNA. 1µg DNA was added to various activity units of DNase I in a total reaction volume of 10µL. Compared with competitors 1 and 2, DNase I of KACTUS had a stronger digestive effect. 

    Product List

    Catalog Number

    Product Title

    Sizes

    GMP-BSA-EE101

    BsaI

    20kU/400kU

    GMP-T7P-EE101

    T7 RNA Polymerase

    50kU/1MU

    GMP-VCS-VE101

    Vaccinia Capping Enzyme

    10kU/1MU

    GMP-MEH-VE101

    mRNA Cap 2'-O-Methyltransferase

    50kU/5MU

    GMP-PYR-YE101

    Pyrophosphatase, Inorganic

    100U/800U

    GMP-RNI-ME101

    Murine RNase Inhibitor

    40kU/2.2MU

    GMP-DNI-EE001

    DNase I

    4kU/40kU


    More from > RNA/DNA

    Explore more

  • RNA/DNA
  • Popular posts